Pharma channel feed

US spent $3B on DMD treat­ments as con­fir­ma­to­ry stud­ies still un­der­way, JA­MA pa­per says

Last year
FDA+

Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Last year
R&D

Mar­ket­ingRx roundup: Pfiz­er, Lil­ly lead Acad­e­my Awards phar­ma ads; Merz Aes­thet­ics teams with De­mi Lo­va­to

Last year
Marketing

Mer­ck pens pact with Pearl Bio for new bi­o­log­ics in can­cer

Last year
Startups
Deals

Biden ad­min­is­tra­tion pro­pos­es fund­ing bump for FDA, nix­ing in­ter­change­abil­i­ty re­quire­ment

Last year
FDA+

Oth­er IRA cas­es could be in­flu­enced by New Jer­sey judge's de­ci­sions, ex­pert says

Last year
Law

CBO hints that Medicare may soon cov­er obe­si­ty drugs for their car­dio­vas­cu­lar ben­e­fits

Last year

Vi­a­tris and Mapi eval­u­ate next steps af­ter FDA re­jects long-act­ing MS in­jec­tion

Last year
FDA+

UCB de­buts first cam­paign for pso­ri­a­sis drug Bimzelx dur­ing Os­cars

Last year
Marketing

Lex­i­con gears up for an­oth­er shot in di­a­betes as path for­ward agreed with FDA

Last year
R&D

Five ques­tions on the fu­ture of Lil­ly’s Alzheimer’s drug, from Dunn’s lega­cy to ARIA

Last year

Phar­ma bris­tles at Biden’s call to ex­pand IRA ne­go­ti­a­tions at State of the Union

Last year
FDA+

BeiGene files patent suits against San­doz, MSN Group

Last year
Law

J&J opens SXSW as health spon­sor

Last year
Marketing

Akero ex­ec­u­tives point to ad­vanced fi­bro­sis pa­tients for MASH drug

Last year
R&D

Up­dat­ed: FDA ap­proves weight loss drug We­govy to re­duce car­dio­vas­cu­lar events

Last year
FDA+

Gilead­'s on­col­o­gy cam­paign spot­lights metasta­t­ic breast can­cer pa­tients who of­ten feel un­seen

Last year
Marketing

Up­dat­ed: Phar­ma com­pa­nies present IRA cas­es in New Jer­sey court

Last year
Law

Law­mak­ers call for 'line in the sand' be­tween US and Chi­nese biotech com­pa­nies

Last year
China
Law

BeiGene’s Brukin­sa bags fifth FDA ap­proval, like­ly po­si­tion­ing it for con­tin­ued sales growth

Last year
FDA+

Lil­ly push­es back on the pop cul­ture clam­or for obe­si­ty drugs in new TV ads

Last year
Marketing

Boehringer In­gel­heim caps in­haler out-of-pock­et costs at $35 af­ter po­lit­i­cal pres­sure

Last year

Bris­tol My­ers nabs ap­proval for Op­di­vo com­bo as first-line blad­der can­cer treat­ment

Last year
R&D
FDA+

No­vo touts ear­ly da­ta for next-gen oral weight loss drug as it out­lines next steps

Last year
R&D
First page Previous page 68697071727374 Next page Last page
A service from the Financial Times